FLASCO

 

Corporate Members

Diamond Elite

Diamond

Platinum

Gold

Silver

Latest News

astrazeneca

FDA APPROVES NEW TREATMENT FOR PATIENTS WITH UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER FOLLOWING CRT

We are pleased to inform you that the US Food and Drug Administration (FDA) has approved IMFINZI® (durvalumab) for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). There have been limited options over the past 10 years...

astrazeneca

FDA expands approval of AstraZeneca’s Imfinzi to reduce the risk of non-small cell lung cancer progressing

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation). “This is the first treatment approved for stage III...

The U.S. Food and Drug Administration approved Janssen’s Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant).

The U.S. Food and Drug Administration approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. “The FDA evaluates a variety of methods that measure a drug’s...

Florida Cancer Specialists Physicians Address Community Oncology Alliance National Briefing

WASHINGTON, D.C. – February 12, 2018. . . . . . . . .On Wednesday, February 7th, the Community Oncology Alliance(COA) hosted a “State of the Union” briefing at the National Press Club in Washington, DC on the current status of community oncology in the United States. Florida Cancer Specialists (FCS) physician leaders Dr. Michael...

Dr. Diane Cope Publishes Article Examining Role of Advanced Practitioner In Maintaining Patient Adherence on Oral Oncolytics

Fort Myers, FL – February 12, 2018…… Florida Cancer Specialists (FCS) Director of Nursing Diane Cope, PhD, ARNP, BC, AOCNP, was second author of a review and interventional article that examined the role of the Advanced Practitioner (AP) in maintaining compliance in patients taking oral oncolytics.  Published recently in the Journal of the Advanced Practitioner...

Who’s Online

Profile picture of FLASCO